Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Active Project Grant Awarded Last action
- Award ID
- R44TR005137
- Recipient
-
Cellchorus Inc. UEI LUF6ANBGK7F4
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,340,714
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date 84% complete
- Originally
- Place of performance
- Houston, TX 77023, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cell and gene therapies have revolutionized treatment options for patients with pace of discovery and implementation accelerating. For example, clinical success of car-T cells for hematologic malignancies has led to use in expanded patient populations and trials targeting for other cancer types. While there are many cell therapies in preclinical development and clinical trials confidence in their successes is undermined by the inherent complexity of cells that remains difficult to decipher using existing tools. What is needed is an integrated analytical platform providing a matrix of readouts that reveal an in-depth real-time understanding of cell phenotype and metabolism. Such a platform will inform on the therapeutic potential before administration and by sampling patients will reveal aspects of cell behavior that correlate with efficacy. Cellchorus is answering this need using our platform ("timing") to undertake large scale single-cell analyses to track and characterize behavior of immune cells over time. Timing uses sophisticated AI-based software, many years in development, to track and characterize behaviors of thousands of cells in parallel using time-lapse imaging. Multiple papers and repeat customers have helped validate our approach to commercialization. Based on users' demand, we propose to advance timing by (I) developing and optimizing reagents and protocols to identify a suite of cell surface attributes, (II) quantify proliferative capacity and (III) determine metabolic activity before, during, and after cell-cell interactions. We will integrate these findings with our AI software to provide end users with a simple, unified assay system to run in their own laboratories on commercially available imaging instrumentation. The results of this project will be ready-to-use kits to reveal critical immune-biology of cells in critical and challenging environments. This is predicted to augment translational research and development leading to improvements in manufacturing and success in patients.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,034,752 | |
| Amendment | $1,034,752 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $984,242 | |
| Amendment | $984,242 | |
| Amendment | $984,242 | |
| Amendment | $984,242 | |
| Amendment | $984,242 | |
| Original award | $350,000 |
Show all 17
Quick answers
Who received award R44TR005137?
R44TR005137 was awarded to Cellchorus Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on May 1, 2024.
How much is award R44TR005137 worth?
$7,340,714 has been obligated on R44TR005137.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award